NO985977L - Spiro-piperidinderivater og deres anvendelse som terapeutiske midler - Google Patents

Spiro-piperidinderivater og deres anvendelse som terapeutiske midler

Info

Publication number
NO985977L
NO985977L NO985977A NO985977A NO985977L NO 985977 L NO985977 L NO 985977L NO 985977 A NO985977 A NO 985977A NO 985977 A NO985977 A NO 985977A NO 985977 L NO985977 L NO 985977L
Authority
NO
Norway
Prior art keywords
spiro
piperidine derivatives
therapeutic agents
emesis
migraine
Prior art date
Application number
NO985977A
Other languages
English (en)
Norwegian (no)
Other versions
NO985977D0 (no
Inventor
Raymond Baker
Neil Roy Curtis
Jason Matthew Elliott
Timothy Harrison
Gregory John Hollingworth
Philip Stephen Jackson
Janusz Jozef Kulagowski
Eileen Mary Seward
Christopher John Swain
Brian John Williams
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9613108.1A external-priority patent/GB9613108D0/en
Priority claimed from GB9625051A external-priority patent/GB9625051D0/en
Priority claimed from GBGB9626593.9A external-priority patent/GB9626593D0/en
Priority claimed from GB9701459A external-priority patent/GB9701459D0/en
Priority claimed from GBGB9710743.7A external-priority patent/GB9710743D0/en
Priority claimed from GBGB9710747.8A external-priority patent/GB9710747D0/en
Priority claimed from GBGB9710748.6A external-priority patent/GB9710748D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NO985977D0 publication Critical patent/NO985977D0/no
Publication of NO985977L publication Critical patent/NO985977L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO985977A 1996-06-21 1998-12-18 Spiro-piperidinderivater og deres anvendelse som terapeutiske midler NO985977L (no)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9613108.1A GB9613108D0 (en) 1996-06-21 1996-06-21 Therapeutic agents
GB9625051A GB9625051D0 (en) 1996-12-02 1996-12-02 Therapeutic agents
GBGB9626593.9A GB9626593D0 (en) 1996-12-20 1996-12-20 Therapeutic agents
GB9701459A GB9701459D0 (en) 1997-01-24 1997-01-24 Therapeutic agents
GBGB9710743.7A GB9710743D0 (en) 1997-05-23 1997-05-23 Therapeutic agents
GBGB9710747.8A GB9710747D0 (en) 1997-05-23 1997-05-23 Therapeutic agents
GBGB9710748.6A GB9710748D0 (en) 1997-05-23 1997-05-23 Therapeutic agents
PCT/GB1997/001630 WO1997049710A1 (en) 1996-06-21 1997-06-17 Spiro-piperidine derivatives and their use as therapeutic agents

Publications (2)

Publication Number Publication Date
NO985977D0 NO985977D0 (no) 1998-12-18
NO985977L true NO985977L (no) 1999-02-22

Family

ID=27562932

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985977A NO985977L (no) 1996-06-21 1998-12-18 Spiro-piperidinderivater og deres anvendelse som terapeutiske midler

Country Status (19)

Country Link
US (1) US6071927A (xx)
EP (1) EP0906315A1 (xx)
JP (1) JP2000510153A (xx)
KR (1) KR20000022060A (xx)
AU (1) AU722541B2 (xx)
BG (1) BG102998A (xx)
BR (1) BR9709915A (xx)
CA (1) CA2257964A1 (xx)
CZ (1) CZ424798A3 (xx)
EA (1) EA001574B1 (xx)
EE (1) EE9800459A (xx)
IL (1) IL126900A0 (xx)
NO (1) NO985977L (xx)
NZ (1) NZ332777A (xx)
PL (1) PL330235A1 (xx)
SK (1) SK175398A3 (xx)
TR (1) TR199802667T2 (xx)
WO (1) WO1997049710A1 (xx)
YU (1) YU59098A (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715558B2 (en) * 1995-11-23 2000-02-03 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as tachykinin antagonists
ATE265209T1 (de) * 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
US5929094A (en) * 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) * 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
JP2001504852A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 双極性障害の治療のためのｎｋ−１受容体拮抗薬の使用
CA2287487A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating eating disorders
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
CA2298779A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
GB9812617D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
GB9902881D0 (en) 1999-02-09 1999-03-31 Merck Sharp & Dohme Therapeutic agents
GB0004699D0 (en) 2000-02-28 2000-04-19 Merck Sharp & Dohme Chemical synthesis
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
DE10040051A1 (de) * 2000-08-11 2002-02-21 Basf Ag Derivate des 4-(Trifluormethyl)-phenols sowie Derivate des 4-(Trifluormethylphenyl)-2-(tetrahydropyranyl)ethers und Verfahren zu ihre Herstellung
US20020103110A1 (en) * 2001-01-26 2002-08-01 Spitzer A. Robert System and method for rectal administration of medication for treatment of migraines
GB0108973D0 (en) * 2001-04-10 2001-05-30 Merck Sharp & Dohme Therapeutic agents
GB0121874D0 (en) * 2001-09-10 2001-10-31 Merck Sharp & Dohme Therapeutic agents
US6673792B1 (en) * 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2573271C (en) 2004-07-15 2015-10-06 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0613403A2 (pt) 2005-07-15 2009-02-10 Amr Technology Inc tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
BRPI0807972A2 (pt) 2007-01-24 2014-06-10 Glaxo Group Ltd Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
ES2662072T3 (es) 2009-05-12 2018-04-05 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
US9505718B2 (en) 2013-03-15 2016-11-29 Nanyang Technological University 3-piperidone compounds and their use as neurokinin-1 (NK1) receptor antagonists
WO2022015628A2 (en) * 2020-07-15 2022-01-20 St. Jude Children's Research Hospital, Inc. Obese ferret model and methods of establishing and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69412067T2 (de) * 1993-01-28 1999-03-25 Merck & Co Inc Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
ATE166650T1 (de) * 1993-03-04 1998-06-15 Pfizer Spiroazacyclischderivate als substanz p antagonisten
CA2163995A1 (en) * 1993-06-07 1994-12-22 Malcolm Maccoss Spiro-substituted azacycles as neurokinin antagonists
GB9417956D0 (en) * 1994-09-02 1994-10-26 Merck Sharp & Dohme Therapeutic agents
GB9426103D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Therapeutic agents
AU715558B2 (en) * 1995-11-23 2000-02-03 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as tachykinin antagonists

Also Published As

Publication number Publication date
SK175398A3 (en) 2000-04-10
JP2000510153A (ja) 2000-08-08
WO1997049710A1 (en) 1997-12-31
AU722541B2 (en) 2000-08-03
YU59098A (sh) 2002-06-19
AU3102097A (en) 1998-01-14
BR9709915A (pt) 1999-08-10
US6071927A (en) 2000-06-06
PL330235A1 (en) 1999-05-10
EA199900045A1 (ru) 1999-06-24
EA001574B1 (ru) 2001-06-25
BG102998A (en) 1999-09-30
KR20000022060A (ko) 2000-04-25
NZ332777A (en) 2000-06-23
TR199802667T2 (xx) 1999-03-22
NO985977D0 (no) 1998-12-18
EP0906315A1 (en) 1999-04-07
CA2257964A1 (en) 1997-12-31
EE9800459A (et) 1999-06-15
IL126900A0 (en) 1999-09-22
CZ424798A3 (cs) 1999-05-12

Similar Documents

Publication Publication Date Title
NO985977L (no) Spiro-piperidinderivater og deres anvendelse som terapeutiske midler
MX9701305A (es) Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas.
DE122008000037I1 (de) Morpholinwirkstoffvorläufer als tachykininreceptorantagonisten
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
HK1008819A1 (en) Piperidine derivatives as neurokinin antagonists
DK0681571T3 (da) Spiro-substituerede azacykliske forbindelser som tachykininreceptorantagonister
DK0662958T3 (da) 1-(2-Oxoacetyl)piperidin-2-carboxylsyrederivater som multilægemiddelresistente cancercellesensibiliserende midler
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
NO972910L (no) Tetracykliske spiroforbindelser, fremgangsmåte for fremstilling og anvendelse derav som 5HT1D reseptor-antagonister
NO963731L (no) Behandling av obsessive-kompulsive sykdommer med 5HT2-antagonister
MY133503A (en) Selective iglur5 receptor antagonists for the treatment of migrane
NO984740L (no) Isatinderivater som acetylcholinesteraseinhibitorer og analgetiske midler
NO973652L (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist
NO931342L (no) Benzimidazoler, medisinske preparater inneholdende disse,og fremgangsmaate for deres fremstilling
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
NO981131L (no) Diarylalkenylamin-derivater
NO982863L (no) Nye forbindelser med analgetisk effekt
DE69717969D1 (de) Substituierte n-methyl-n-(4-(piperidin-1-yl)-2-arylbutyl)-benzamide zur behandlung von allergischen erkrankungen
NO932002L (no) Nye tiosemikarbazonsyreestere
ECSP972326A (es) Derivados de espiro - piperidina y su uso como agentes terapeuticos

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application